Pyoderma Gangrenosum in Pregnancy Often Misdiagnosed
A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions.
METHODOLOGY:
Researchers conducted a systematic review of 62 studies describing 63 patients (average age, 29.9 years) with PG during pregnancy or up to 6 weeks postpartum through September 2023.
Of all patients, 27% of patients had a history of PG or PG-like symptoms, 7.9% had a history of inflammatory bowel disease, and 4.8% had another systemic rheumatologic disease. In 71.4% of cases, preceding trauma to the skin was reported.
Outcomes included the misdiagnosis rate, treatment, and maternal and fetal complications.
TAKEAWAY:
During pregnancy, 15.9%, 11.1%, and 7.9% of cases appeared in the first, second, and third trimesters, respectively, while 65.1% were postpartum — primarily at the site of cesarean section scars (55.6%).
Of the 47 cases where an initial diagnosis was reported, only 2 cases were recognized as PG; 45 (95.7%) were initially misdiagnosed as bacterial infections, necrotizing fasciitis, or another skin disorder. Among the 26 cases with data on time to diagnosis, the diagnosis was delayed by more than 7 days in 77%.
Before the diagnosis of PG, surgical wound intervention and broad-spectrum antibiotics were the most frequent treatments, whereas systemic corticosteroids (88.9%) and cyclosporine (33.3%) were most commonly used after PG was diagnosed. All patients showed improvement after treatment, and treatment-related adverse effects were uncommon.
Cesarean section was performed in 40 cases, and 22 of 41 cases with gestational age data were preterm, and there was one case of intrauterine fetal demise.
IN PRACTICE:
These results highlighted 'the frequent misdiagnosis of PG in this population, leading to treatment delays and inappropriate interventions that worsen the condition,' the authors of the study wrote. The study, 'supported by immunological research,' suggested that pregnancy 'may independently contribute to the development of PG,' they added, noting that further research on safe and effective treatment protocols is needed.
SOURCE:
This study was led by Gretchen D. Ball, and Sarah Romanelli, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, and was published online on June 30 in the Journal of Drugs in Dermatology.
LIMITATIONS:
This study was limited by its small sample size and inconsistencies in data reporting across case reports. Collecting comprehensive pregnancy outcomes data was challenging due to limited pregnancy details provided in dermatology journals.
DISCLOSURES:
This study was supported by the International Dermatology Outcome Measures nonprofit group. One author disclosed receiving grants and honoraria, and holding stocks in various organizations, including Amgen, AnaptysBio, Avotres Therapeutics, Eli Lilly and Company, Novartis, Sanofi, and XBiotech.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
EMA Recommends Aqneursa for Niemann-Pick Type C Disease
At its July 2025 meeting, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorization in the European Union for Aqneursa (IntraBio Ireland Ltd) for the treatment of neurologic manifestations of Niemann-Pick type C (NPC) disease. The treatment can be used in combination with miglustat, or as a monotherapy for patients in whom miglustat is not tolerated, in adults and children aged 6 years and older and weighing at least 20 kg, the CHMP said. It also pointed out that miglustat is the only medicine authorized to treat NPC disease and has been shown to slow the general progression of neurologic symptoms in patients. NPC disease is a rare, progressive, and fatal genetic disorder caused by mutations encoding lysosomal proteins that are essential for the intracellular transport and metabolism of body fats, including cholesterol. Over time, the cells of the central nervous system and the body organs stop working. There are no curative therapies for NPC disease. The course of the disease varies highly depending on the age of onset, but most patients with NPC disease are children and die before the age of 20. Improvement in Neurologic Signs, Symptoms, and Functioning The active substance of Aqneursa is levacetylleucine, a modified form of the amino acid leucine that targets underlying processes of neurologic dysfunction. Although the mechanism of action of levacetylleucine is not yet fully understood, nonclinical studies have demonstrated that it corrects energy metabolism. This includes improved production of adenosine triphosphate, the main source of energy for cerebellar tissues and cells. A randomized, double-blind, placebo-controlled, two-period crossover phase 3 study demonstrated that levacetylleucine offered improvement in neurologic signs, symptoms, and functioning — measured using the Scale for the Assessment and Rating of Ataxia — in patients with NPC disease after 12 weeks of treatment compared with placebo. For the study, 60 patients aged 4 years or older with a confirmed diagnosis of NPC disease and at least mild disease-related neurologic symptoms were randomized in a 1:1 ratio to receive either levacetylleucine or placebo for 12 weeks. For the second 12 weeks, patients were switched to the opposite: either placebo or levacetylleucine. At the end of the first 12 weeks, patients treated with levacetylleucine demonstrated a statistically significant improvement compared with those treated with placebo. At the end of the second 12 weeks, patients who switched from levacetylleucine to placebo experienced a significant worsening of symptoms. The only adverse event causally related to treatment with levacetylleucine is flatulence. The drug will be available as 1-g granules for oral suspension. Rob Hicks is a retired National Health Service doctor. A well-known TV and radio broadcaster, he has written several books and has regularly contributed to national newspapers, magazines, and online publications. He is based in the United Kingdom.
Yahoo
a day ago
- Yahoo
Life might have come from outer space, scientist say
The seeds of life on Earth might have come from outer space – and might be widespread throughout the rest of the universe, scientist say. Researchers have found complex organic molecules in a disc around a 'protostar' in a major breakthrough. Those molecules are seen as the precursors to the building blocks of life, which go on to become sugars and amino acids that are then combined into the complex flora and fauna that surrounds us. Researchers have found such complex organic molecules in other places before. But the new findings fill in a previously mysterious missing link – one that could suggest that life is more abundant than we realise. When cold protostar becomes a young star, surrounded by a disc of dust and gas, it is a violent process that includes intense radiation and the hurling out of gas. Researchers had been concerned that the extreme nature of that process could 'reset' the chemical compounds available around a star, meaning that they would have to be formed in the discs that at the same time are making planets. But the new findings suggest that complex molecules can stick around through that process, meaning they will be inherited by the discs that follow. The findings are reported in a new study, 'A deep search for Complex Organic Molecules toward the protoplanetary disk of V883 Ori', published in the The Astrophysical Journal Letters.
Yahoo
a day ago
- Yahoo
Study Says That 'Micro-Walks' May Be More Effective Than Longer Ones—Even For Weight Loss
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." For years, doctors have stressed the importance of being active during your day—after all, research has found that sitting for too long raises your risk of a slew of serious health conditions, including cardiovascular disease and type 2 diabetes. But the idea of going for hour-long walks can be overwhelming. Now, new research suggests you don't need to jam in a massive stroll into each day: Instead, you can go for 'micro-walks.' That's the main takeaway from a study published in Proceedings of the Royal Society B, which found that micro-walks may be even better for you than long ones. Here's the deal. Interested in making walks part of your regular fitness routine? Check out the exclusive WH+ 4-Week Walking Plan that burns fat and builds muscle at the same time. What are 'micro-walks'? In this study, a 'micro-walk' is defined as walking between 10 and 30 seconds at a time (with breaks in between your next walk). Are 'micro-walks' more beneficial for your health? Why? It depends on how you're looking at it. In this particular study, volunteers walked on a treadmill or climbed a short flight of stairs for different periods of time, ranging from 10 seconds to four minutes. The study participants wore masks to measure their oxygen intake (which can be used to calculate energy or calorie consumption). The researchers discovered that people who walked in short bursts used up to 60 per cent more energy than longer ones, despite the walks covering the same distance. (The more energy you expend, the more calories you can burn.) Basically, you may be able to rev up your metabolism and burn more calories if you do short bursts of walking versus longer cruises around. Albert Matheny, RD, CSCS, a co-founder of SoHo Strength Lab, says there's something to this. 'Getting activity throughout the day, in general, is better for people,' he says. 'It's better for circulation, mental health, and digestive health.' You're also more likely to have a faster pace when you do shorter bursts of walking than if you're going on, say, a five-mile walk, he points out. How many steps should I get per day? This is debatable, and research has shown that the often-quoted 10,000 steps a day may not be necessary. Instead, 7,500 steps or so is ideal—but everyone is different. If you've already been walking, Matheny says that aiming for 10,000 steps a day is great. But if not or if you don't have many opportunities to walk during your day, 7,500 steps may be a better goal. 'It's really about doing what you can,' he says. 'If you're not a big walker and you think, 'I don't want to walk five miles,' then just do 30-second bursts. It's more attainable.'DMX Comfort+ Sneaker $108.49 at 26 $109.95 at 2 $240.00 at You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
